Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
Neon Therapeutics, Inc. (NTGN) Create: Alert

All | News | Filings
Date FiledTypeDescription
05/06/2020 8-K Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta...
Docs: "Amended and Restated Certificate of Incorporation of the Company",
"Senior Manager Global External Communications"
05/05/2020 8-K Submission of Matters to a Vote of Security Holders
04/29/2020 8-K Other Events
03/02/2020 8-K Quarterly results
01/16/2020 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "Agreement and Plan of Merger, by and among Neon Therapeutics, Inc., BioNTech SE, and Endor Lights, Inc",
"Form of Voting Agreement",
"BioNTech to acquire Neon to strengthen global leadership position in T cell therapies"
11/20/2019 8-K Quarterly results
11/12/2019 8-K Quarterly results
11/08/2019 8-K Quarterly results
08/06/2019 8-K Quarterly results
Docs: "Neon Therapeutics Reports Second Quarter 2019 Financial Results Planning to present more detailed data from NT-001 clinical trial evaluating NEO-PV-01 in advanced or metastatic melanoma, non-small cell lung and bladder cancers at an upcoming medical society meeting Announces U.S. Food & Drug Administration clearance of Neon’s Investigational New Drug application for off-the-shelf candidate, NEO-SV-01, for a genetically-defined subset of hormone receptor-positive breast cancer Planning to file a Clinical Trial Application in Europe in the second half of 2019 to evaluate personal neoantigen T cell therapy candidate, NEO-PTC-01, in refractory solid tumor settings"
07/15/2019 8-K Other Events, Financial Statements and Exhibits
Docs: "Neon Therapeutics’ Personal Neoantigen Vaccine Study Demonstrates Prolonged Progression-Free Survival in Advanced or Metastatic Melanoma, Non-Small Cell Lung and Bladder Cancers NEO-PV-01, in combination with OPDIVO® , broadens the immune response to specific new cancer targets, leading to the first demonstration of improved clinical durability for a personal neoantigen-based therapy in the metastatic cancer setting Demonstrated prolonged and consistent improvements in progression-free survival that compare favorably to historical monotherapy checkpoint inhibitor data in each of the three distinct tumor types in trial of NEO-PV-01 Median PFS not yet reached at 13.4-month median follow-up in metastatic melanoma; median PFS of 5.6 months in metastatic non-small cell lung cancer; and median P..."
06/20/2019 8-K Submission of Matters to a Vote of Security Holders
05/13/2019 8-K Quarterly results
Docs: "Neon Therapeutics Reports First Quarter 2019 Financial Results and Provides Clinical Update Advancing a class-leading position in neoantigen-based therapies with ongoing progress across its multiple clinical-stage programs, pre-clinical pipeline and bioinformatics engine Expect to report in July top-line clinical results, including 12-month follow-up, from NT-001 trial of personal neoantigen vaccine NEO-PV-01 in metastatic melanoma, non-small cell lung and bladder cancers Completed enrollment in NT-002 trial of NEO-PV-01, in combination with standard of care, in first-line metastatic non-small cell lung cancer, with data expected in 2020 Continued pipeline progress with near-term expected submissions of clinical trial applications for personal T cell therapy program, NEO-PTC-01 and off-the..."
03/11/2019 8-K Quarterly results
01/22/2019 8-K Other Events
11/13/2018 8-K Quarterly results
Docs: "Neon Therapeutics Reports Third Quarter 2018 Financial Results and Recent Business Highlights"
11/09/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "Investor Presentation by Neon Therapeutics, Inc."
11/07/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Neon Therapeutics Appoints Industry Veteran Robert Bazemore to its Board of Directors"
10/22/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "Investor Presentation by Neon Therapeutics, Inc."
10/17/2018 8-K Quarterly results
08/06/2018 8-K Quarterly results
Docs: "Neon Therapeutics Reports Second Quarter 2018 Financial Results and Recent Business Highlights"
06/29/2018 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
Docs: "Amended and Restated Certificate of Incorporation of Neon Therapeutics, Inc",
"Amended and Restated Bylaws of Neon Therapeutics, Inc"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy